Back

The effect of eplerenone on the disease onset and progression of phospholamban cardiomyopathy in presymptomatic mutation carriers: results of the i-PHORECAST trial

28 August 2022 (10:15 - 10:55)
Organised by:
Congress Presentation Part of: Anticoagulant therapy: real world use and clinical challenges Aldosterone Antagonists ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Mr Remco De Brouwer

University Medical Centre Groningen, Groningen (Netherlands (The))

4 More presentations in this session

Presentation thumbnail
Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: a nationwide cohort study
Mr M. Grymonprez (Gent, BE)
Abstract Slides
Presentation thumbnail
Oral anticoagulation in patients with atrial fibrillation and stage IV and V chronic kidney disease: a systematic review and meta-analysis
Doctor A. Miranda-Arboleda (Boston, US)
Abstract Slides
Presentation thumbnail
The real-world effectiveness and safety of edoxaban treatment in 27,333 Global ETNA-AF programme patients with and without a history of heart failure
Professor J. Siller-Matula (Vienna, AT)
Abstract Slides
Presentation thumbnail
Potentially inappropriate prescribing and its demographic and clinical correlates in older adults with atrial fibrillation: a population-based study
Ms C. Amrouch (Ghent, BE)
Abstract Slides

Access the full session

Session thumbnail
Anticoagulant therapy: real world use and clinical challenges

The Event

Event poster

ESC Congress 2022

28 August 2022 10:15 CET
You may be interested in
thumbnail
Webinar
MRAs in heart failure: what's old is new again
thumbnail
Congress Presentation
Aldosterone-targeted therapies in hypertension
thumbnail
Congress Session
Does aldosterone synthase inhibition hold a key to transforming cardiorenal care?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources